Mar 05, 2019 / 02:50PM GMT
John Wilson Ransom - Raymond James & Associates, Inc., Research Division - MD of Equity Research & Director of Healthcare Research
Good morning. I'm John Ransom of Raymond James. We are pleased to host Charles River, who was very gracious to honor us with their presence this year, despite some analyst turnover. Those who know me know me, I'm not usually on script, but I'm going to be on script here because I don't cover Charles River, but it's obviously an interesting company. So for those of you who don't know it, it is an early stage CRO focusing on animal health testing. More recently, they've taken pains to build out more of an end-to-end product. Stock has been terrific, up about 35% over the past year. And we know the company is one of the 2 or 3 leaders in really what's a great niche. So with that, I'll turn it over.
James C. Foster - Charles River Laboratories International, Inc. - Chairman, CEO & President
Thank you. Always a pleasure to be here. So safe harbor and Reg G statements. So as you just said, we're the largest nonclinical CROs. We
Charles River Laboratories International Inc at Raymond James Institutional Investors Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot